In-Utero Endoscopic Correction of Spina Bifida

Spina Bifida Clinical Trial

Official title:

In-Utero Endoscopic Correction of Spina Bifida: Laparotomy-Assisted or Percutaneous

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04362592
• Other study ID #: HS-05-00374
• Status: Recruiting
• Phase: N/A
• Start date: November 2, 2018
• Est. completion date: October 31, 2031

Study information

• Verified date: June 2023
• Source: University of Southern California
• Contact: Ruben Quintero, MD
• Phone: 720-753-3825
• Email: q[@]the-fetal-institute.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the feasibility and effectiveness of performing fetoscopic surgical correction of fetal spina bifida. Two surgical approaches will be utilized: the percutaneous technique versus the laparotomy/uterine exteriorization technique.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 110
• Est. completion date: October 31, 2031
• Est. primary completion date: June 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 52 Years

Eligibility

Inclusion Criteria:

1. Myelomeningocele (including myeloschisis) at level T1 through S1 with hindbrain herniation. Lesion level and hindbrain herniation will be confirmed by MRI and ultrasonography.

2. Maternal age =18 years.

3. Gestational age of 19 to 27 6/7 weeks' gestation as determined by clinical information and evaluation of first ultrasound.

4. Balanced karyotype and/or normal mircoarray with written confirmation of culture results. Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is at 24 weeks or more.

5. Positive evaluation of social work consult indicating the patient is capable of consenting to the procedure and has the appropriate social support system to participate in the study.

6. Positive evaluation from pediatric neurology consult.

7. Willing to return to our center, or to a multi-disciplinary spina bifida clinic closer to their home for the 6, 12, 24, 30, 48, and 60 months follow-up evaluations.

Exclusion Criteria:

1. Multiple gestation

2. Insulin-dependent pregestational diabetes

3. Presence of a fetal anomaly not related to Chiari II Malformation. A fetal echocardiogram will be conducted before surgery and if the finding is abnormal, the patient will be excluded.

4. Fetal kyphosis of 30 degrees or more, assessed by ultrasound or MRI.

5. Presence of uterine cervical cerclage or history of incompetent cervix.

6. Placenta previa or placental abruption.

7. Short cervix < 25 mm measured by cervical ultrasound.

8. Obesity as defined by body mass index (BMI) of 40 or greater.

9. History of previous spontaneous singleton delivery prior to 37 weeks.

10. Maternal-fetal Rh isoimmunization, Kell sensitization or a history of neonatal alloimmune thrombocytopenia.

11. Maternal HIV or Hepatitis-B status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis B status is unknown, the patient must be tested and found to have negative results before she can be enrolled.

12. Known Hepatitis-C positivity. If the patient's Hepatitis C status is unknown, she does not need to be screened.

13. Uterine anomaly such as large (greater than 6 cm) fibroids, cervical fibroids or multiple fibroids or Mullerian duct abnormality.

14. Other maternal medical condition which is a contraindication to surgery or anesthesia.

15. Patient does not have a support person (e.g., husband, partner, parents).

16. Inability to comply with the travel and follow-up requirements of the study.

17. Patient does not meet psychosocial criteria as determined by the social worker evaluation.

18. Participation in another intervention study that influences maternal and fetal morbidity and mortality.

19. Maternal hypertension as determined by the investigator, which would increase the risk of preeclampsia or preterm delivery (including, but not limited to: uncontrolled hypertension, chronic hypertension with end organ damage and new onset hypertension in current pregnancy).

20. Bicornuate uterus or any other uterine malformation the PI decides is not safe for surgery.

21. Nickel allergy.

22. Maternal request to undergo open fetal surgery for the antenatal correction of OSB at our institution primarily or after failed fetoscopic approach.

23. Known maternal hypersensitivity to bovine collagen or chondroitin materials.

Related Conditions & MeSH terms

• Meningomyelocele
• Myelomeningocele
• Neural Tube Defects
• Spina Bifida
• Spinal Dysraphism

Intervention

Device:
• In Utero Endoscopic Correction of Myelomeningocele IDE - Percutaneous Technique
The percutaneous approach uses endoscopes through a closed maternal abdomen and closed uterus to perform the spina bifida correction.
• In Utero Endoscopic Correction of Myelomeningocele IDE - Laparotomy/Uterine Exteriorization Technique
The laparotomy/uterine exteriorization technique uses endoscopes through an open abdomen and closed, exteriorized uterus to perform the spina bifida correction.

Locations

Country	Name	City	State
United States	Hollywood Presbyterian Medical Center	Los Angeles	California
United States	Wellington Regional Medical Center	Wellington	Florida

Sponsors (2)

Lead Sponsor	Collaborator
University of Southern California	USFetus

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ability to perform the endoscopic procedure	Successful fetoscopic closure of the defect	At time of surgery
Secondary	Chiari II malformation reversal	Reversal of hindbrain herniation on ultrasound and MRI	Prior to delivery